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Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in
the Framingham Heart Study
Michelle T. Long, MD; Xiaoyan Yin, PhD; Martin G. Larson, PhD; Patrick T. Ellinor, MD, PhD; Steven A. Lubitz, MD, MPH; David D. McManus,
MD; Jared W. Magnani, MD, MSc; Laila Staerk, MD, PhD; Darae Ko, MD; Robert H. Helm, MD; Udo Hoffmann, MD; Raymond T. Chung, MD;
Emelia J. Benjamin, MD, ScM
Background-—Obesity is an important risk factor for nonalcoholic fatty liver disease and atrial ﬁbrillation (AF). Less is known about
the relations between nonalcoholic fatty liver disease and AF. We sought to evaluate the association between fatty liver and
prevalent and incident AF in the community.
Methods and Results-—We examined Framingham Heart Study participants who underwent a study-directed computed
tomography scan, had hepatic steatosis (HS) evaluated, and did not report heavy alcohol use between 2002 and 2005. We
evaluated cross-sectional associations between liver fat and prevalent AF with logistic regression models. We assessed the
relations between liver fat and incident AF during 12-year follow-up with Cox proportional hazards models. Of 2122 participants
(53% women; mean age, 59.09.6 years), 20% had HS. AF prevalence (n=62) among individuals with HS was 4% compared to 3%
among those without HS. There was no signiﬁcant association between HS (measured as continuous or dichotomous variables) and
prevalent AF in age- and sex-adjusted or multivariable-adjusted models. Incidence of AF (n=153) among participants with and
without HS was 8.7 cases and 7.8 cases per 1000 person-years, respectively. In age- and sex-adjusted and multivariable-adjusted
models, there were no signiﬁcant associations between continuous or dichotomous measures of HS and incident AF.
Conclusions-—In our community-based, longitudinal cohort study, liver fat by computed tomography scan was not signiﬁcantly
associated with increased prevalence or incidence of AF over 12 years of follow-up. ( J Am Heart Assoc. 2017;6: e005227. DOI:
10.1161/JAHA.116.005227.)
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N onalcoholic fatty liver disease (NAFLD), which isassociated with obesity, is now the most common
chronic liver disease in the United States.1 The liver damage
associated with NAFLD ranges from hepatic steatosis (HS) to
ﬁbrosis in the absence of excessive alcohol intake; however,
the leading cause of death in patients with NAFLD is ischemic
heart disease.2–4 NAFLD is associated with an increased risk
for cardiovascular disease, particularly among those with
diabetes mellitus.4 Previous studies have demonstrated that
patients with NAFLD have altered cardiac function and
structure, which may predispose to heart failure and atrial
ﬁbrillation (AF).5–7 Whereas obesity is considered an impor-
tant risk factor for AF,8 less is known about whether NAFLD is
associated with AF after accounting for obesity.
There are several mechanisms that could potentially link
NAFLD and AF beyond shared risk factors. First, NAFLD may
contribute to increased systemic inﬂammation,9 which may
trigger AF.10,11 Second, participants with NAFLD may have
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left ventricular diastolic dysfunction,5–7 which also could
predispose to AF.12 Individuals with NAFLD have an increased
risk of ischemic heart disease,4 which is an established risk
factor for AF. Additionally, intermittent hypoxia from sleep
apnea is associated with an increased severity of NAFLD13
and with increased atrial arrhythmogenicity and AF.14 Finally,
NAFLD is associated with autonomic dysfunction15,16 that
may impact cardiac remodeling and play an important role in
both initiating and maintaining AF.17
Only a limited number of previous studies have related
NAFLD, as deﬁned on computed tomography (CT) or ultra-
sound, with prevalent or incident AF. The results of previous
studies have been conﬂicting, with some studies identifying an
association between elevated liver enzymes, but not imaging-
deﬁned NAFLD, with AF, whereas others reported that
imaging-deﬁned NAFLD was a predictor of AF in select
cohorts.18–22 Methods to prevent AF are incompletely under-
stood,23 and there are data to suggest that weight loss is
associated with a reduced risk of AF.24,25 It is not known
whether methods aimed at reducing hepatic fat may impact
incident AF. Though the interactions between obesity, hepatic
fat, and cardiovascular disease are complex, more studies are
needed to better deﬁne the relations between HS and AF.
Thus, we hypothesize that HS is associated with both prevalent
AF and incident AF over up to 12 years of follow-up in
Framingham Heart Study (FHS) Offspring and Third Generation
cohort participants, after accounting for known AF risk factors.
Methods
Study Sample
Participants were drawn from the FHS Offspring and Third
Generation cohorts who underwent measurement of liver fat
by abdominal multi-detector computed tomography (MDCT)
scan between 2002 and 2005 as a part of a substudy
(Figure 1).26–28 Of the 3475 participants with adequate
measures of liver fat on the MDCT study, we excluded
participants for the following indications: 50 for missing
covariates, 97 for missing serum alanine aminotransferase
(ALT) or aspartate aminotransferase levels (AST), 39 for
history of self-reported heavy alcohol use (deﬁned as
>14 drinks per week for women and >21 drinks per week
for men),29 and 1167 for age ≤45 years, given that the
incidence of AF is low among younger adults.30 The ﬁnal
sample included 2122 individuals. For the analysis of incident
AF, we additionally excluded those with prevalent AF (n=62).
The institutional review boards of Boston University Medical
Center and Massachusetts General Hospital approved of the
protocol. All participants provided written informed consent.
Figure 1. Study sample in the analyses of liver fat with prevalent and incident atrial
ﬁbrillation. AF indicates atrial ﬁbrillation; ALT, alanine aminotransferase; MDCT, multide-
tector computed tomography.
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MDCT Protocol and Measurement of Liver Fat
The MDCT substudy has been described in detail previously.27
Brieﬂy, participants underwent abdominal imaging (Light-
Speed Ultra; General Electric, Milwaukee, WI) in the supine
position with 25 contiguous 5-mm slices (120 kVp, 400 mA;
gantry rotation time, 500 ms; table feed, 3:1) starting at the
upper edge of S1. A radiopaque phantom (Image Analysis,
Lexington, KY) was placed under each participant and
visualized on each image obtained.
We obtained the mean MDCT Hounsﬁeld units (HU) from 3
areas of the liver to determine the average liver HU. We
calculated the liver phantom ratio (LPR) as the ratio between
the average liver HU and the phantom HU as previously
described.31 As the LPR decreases, the amount of fat in the
liver increases. We deﬁned HS by an LPR ≤0.33, which was
shown in our previous work to be highly sensitive and speciﬁc
for detecting liver fat.32
Assessment of AF
All FHS participants underwent an electrocardiogram (ECG) at
each FHS study visit. We also obtained ECGs and Holter
monitor reports from physician ofﬁces and hospital records.
Prevalent AF was deﬁned by the presence of any episode of
conﬁrmed atrial ﬂutter or AF on an ECG or Holter monitor
report before the MDCT substudy. Biennial health history
updates included a question on occurrence of AF. All
prevalent and incident AF cases underwent adjudication by
at least 2 FHS cardiologists.33
Covariates and Baseline Measurements
Covariates and baseline measurements were assessed at the
seventh examination (1998–2001) for the FHS Offspring
Cohort and at the ﬁrst examination (2002–2005) for the FHS
Third Generation Cohort. Alcohol use and smoking status
were assessed on the basis of physician-administrated
questionnaires. Self-reported alcohol use was recorded as
drinks per week or drinks per month. Participants were
considered current smokers if they had smoked at least 1
cigarette per day in the year preceding the FHS examination.
Plasma glucose and serum AST and ALT were obtained from
fasting morning samples using an automated Roche method
(Roche Cobas 501; Roche, Indianapolis, IN). Using standard
protocols, trained technicians measured heart rate, blood
pressure, height, and weight in all participants. Body mass
index (BMI) was deﬁned as weight (kg)/height2 (m2). Diabetes
mellitus was deﬁned as fasting plasma glucose ≥126 mg/dL
or treatment with a hypoglycemic agent or insulin. Heart
failure and myocardial infarction (MI) events were noted at the
FHS clinical encounter with a study physician and from
available medical records. All heart failure and MI events were
adjudicated by a committee of 3 FHS investigators.
Statistical Analysis
For the analysis of the association between liver fat and
prevalent AF, we constructed multiple logistic regression
models adjusting for covariates. We evaluated liver fat as a
continuous variable using the LPR (given that LPR decreases
with increasing liver fat) and as a dichotomous value with an
LPR ≤0.33 deﬁned as HS. The base model was adjusted for
age and sex alone. The multivariable model adjusted for age
and sex and known risk factors for AF,30 including current
smoking, alcohol use, systolic blood pressure, diastolic blood
pressure, antihypertensive medication use, diabetes mellitus,
history of heart failure, and history of MI. Because liver fat is
weakly correlated with BMI (r=0.25),32 we included a third
model, which added adjustment of BMI to the multivariable
model. Results are reported as odds ratios (ORs) with 95%
CIs. All logistic regression models were checked for goodness
of ﬁt using the Hosmer–Lemeshow goodness-of-ﬁt test, and
there was no evidence of lack of ﬁt (P>0.05).
For the analysis of the association between liver fat and
incident AF, we excluded any participant with diagnosed
prevalent AF at baseline assessment. We constructed multi-
variable Cox (proportional hazards) regression models to
assess the relationship between liver fat and incident AF over
up to 12 years of follow-up. Censoring occurred at the time of
death or end of follow-up. As with the prevalent AF analysis
above, we evaluated liver fat as a continuous and dichoto-
mous variable. We also evaluated the incidence of AF among
those with HS (LPR ≤0.33) and increased ALT (deﬁned as
>19 U/L for women and >30 U/L for men)34 at baseline. The
multivariable models were adjusted for covariates in the same
manner as in the prevalent AF analysis. We assessed the
assumption of proportional hazards by calculating a supre-
mum test on the basis of the cumulative sums of Martingale-
based residuals. Results are reported as hazard ratios (HRs)
with 95% CI. Age- and sex-adjusted cumulative AF incidence
curves by HS status were generated for the graphical
representation of data. Cumulative incidence curves were
calculated and adjusted using the corrected group prognostic
method.35 The log-rank test was used to compare the AF
cumulative incidence curves among those with and without
HS at baseline.
Given that we had 153 incident AF cases, a post-hoc power
calculation revealed that we had 80% power to discover an
adjusted HR of 1.27 or larger per presence versus absence of
NAFLD at a 0.05 signiﬁcance level. Analyses were performed
in SAS software (version 9.3; SAS Institute Inc., Cary, NC). A
2-tailed probability value of <0.05 was considered statistically
signiﬁcant.
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Results
Study Sample Characteristics
We present the baseline characteristics of the study sample
(n=2122) in Table 1. The sample included 1120 (53%) women,
and the mean age was 59.09.6 years. Overall, 20% of
participants had HS on MDCT (deﬁned by LPR). Those with HS
had similar ages, but were less often women compared to
those without HS. In general, compared to those without
MDCT HS, individuals with HS had a higher prevalence of
cardiovascular disease risk factors, including higher mean BMI
≥30 kg/m2 and blood pressure, and higher percentages with
hypertension, diabetes mellitus, and history of heart failure or
past MI. Prevalence of AF among those with HS was 4%
compared to 3% among those without HS.
Crude Incidence of AF by HS Status
Mean follow-up durationwas 9.3 years in 19 235 person-years
of observation. During up to 12 years follow-up, 153 partic-
ipants developed AF (Table 2). The overall incidence of AF was
7.95 cases per 1000 person-years. Incidence of AF among
participants with HS on MDCT was 8.7 cases per 1000 person-
years, whereas incidence of AF among participants without HS
on MDCT was 7.8 cases per 1000 person-years.
Association Between Liver Fat and Prevalent AF
There was no signiﬁcant association between fatty liver
(measured as a continuous or dichotomous variable) and
prevalent AF in age- and sex-adjusted or multivariable-adjusted
models (Table 3). Also, those participantswith HS onMDCT and
elevated ALT did not have an increased prevalence of AF
compared to those without both HS and an elevated ALT.
Association Between Liver Fat and Incident AF
In age- and sex-adjusted and multivariable-adjusted models,
there were no signiﬁcant associations between continuous or
dichotomous measures of HS and incident AF (Table 4).
Additionally, participants with both HS and elevated ALT did
not demonstrate an increased incidence of AF in adjusted
models compared to those without both HS and an elevated
ALT. Cumulative hazard curves illustrate incidence of AF for
participants with HS (LPR ≤0.33) compared to those without
HS (LPR >0.33; Figure 2).
Discussion
Principal Findings
In our community-based, longitudinal cohort study, we did not
observe a statistically signiﬁcant association between liver fat
Table 1. Clinical Characteristics at Baseline in the Overall
Sample (n=2122), by HS Status
Clinical
Characteristics Total Sample HS (LPR ≤0.33) No HS (LPR >0.33)
n 2122 423 (20%) 1699 (80%)
Age, y 59.09.6 59.29.3 58.99.7
Women 1120 (53%) 194 (46%) 926 (55%)
Offspring 1244 (59%) 250 (59%) 994 (59%)
Current smoking 221 (10%) 49 (12%) 172 (10%)
Alcohol,
drinks/week
2.63.6 3.14.3 2.53.4
Weight, kg 8018 9018 7817
Height, cm 16910 1699 16910
BMI, kg/m2 28.05.3 31.35.7 27.24.8
Systolic blood
pressure,
mm Hg
12417 12915 12317
Diastolic blood
pressure,
mm Hg
769 7910 759
Hypertension
treatment
554 (26%) 171 (40%) 383 (23%)
Diabetes mellitus 155 (7%) 53 (13%) 102 (6%)
History of
heart failure
15 (0.7%) 6 (1.4%) 9 (0.5%)
History of MI 67 (3%) 18 (4%) 49 (3%)
Prevalent AF 62 (3%) 17 (4%) 45 (3%)
ALT, U/L 27.118.9 34.324.2 25.216.8
Elevated ALT* 962 (45%) 259 (61%) 703 (41%)
AST, U/L 25.514.6 29.323.4 24.511.2
LPR 0.360.05 0.270.06 0.380.02
Data are expressed as meansSD or as number (percentage). AF indicates atrial
ﬁbrillation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body
mass index; HS, hepatic steatosis; LPR, liver phantom ratio; MI, myocardial infarction.
*Elevated ALT is deﬁned as ALT >19 U/L for women and >30 U/L for men.
Table 2. Incidence of AF, by Presence of HS
Total
Sample
HS
(LPR ≤0.33)
No HS
(LPR >0.33) P Value*
Events 153 33 120
Total 2060 406 1654
Person-years 19 235 3801 15 434
AF incidence/1000
person-years
8.0 8.7 7.8 0.56
AF indicates atrial ﬁbrillation; HS, hepatic steatosis; LPR, liver phantom ratio.
*P value describes the differences between those with and without HS.
DOI: 10.1161/JAHA.116.005227 Journal of the American Heart Association 4
Liver Fat and Atrial Fibrillation Long et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on O
ctober 17, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
and prevalent or incident AF after over 19 000 person-years
of observation.
In the Context of the Previous Literature
Previous studies evaluating the association between liver fat
and AF have mostly relied on blood-based surrogate markers
of liver fat, including serum ALT, AST, or gamma glutamyl
transpeptidase (GGT) levels.19,20,36 GGT, a liver enzyme, was
found to be associated with incident AF in the Atheroscle-
rosis Risk in Communities study.36 In a previous investiga-
tion of the FHS Original and Offspring cohorts, elevated ALT
and AST were associated with increased incidence of AF,
over 10 years of follow-up, adjusting for alcohol use.20 There
are several potential explanations for why we did not
conﬁrm the previous ﬁndings. In the previous FHS study,
mean age of participants was 6510 years and those that
developed AF were, on average, 6.8 years older at baseline
compared to those who remained free of AF during the
observation period. The incident rate of AF was 13.2 cases
per 1000 person-years. Our study cohort was derived from
the younger FHS participants in the Offspring and Third
Generation cohorts who participated in the MDCT substudy.
Though we excluded participants aged ≤45 years, the mean
age of our sample was still relatively young at just under
60 years of age. Additionally, increases in ALT, AST, and
GGT are not speciﬁc for liver fat. Elevated levels may be
found in other conditions related to AF, such as alcohol use
or heart failure, so it is possible that the previously reported
associations between ALT, AST, or GGT and AF were driven
by residual confounding from alcohol or comorbid medical
conditions. Additional studies are required in older partici-
pants to examine how generalizable our ﬁndings are across
age categories.
Few studies have assessed the association between
radiographically deﬁned liver fat and AF. In a previous FHS
investigation, there was no association observed between
visceral abdominal fat and prevalent AF in multivariable-
adjusted models, but liver fat was not examined.37 In a
German cohort study including community-dwelling individu-
als, elevated liver enzymes, but not ultrasound-deﬁned HS,
was associated with prevalent AF, which is in line with the
ﬁndings of our study.19 An investigation conducted using data
from a Finnish registry of individuals with hypertension as well
as age- and sex-matched controls showed that ultrasound-
deﬁned HS was associated with a higher odds of incident
AF.18
In our community-based cohort study, we did not demon-
strate a signiﬁcant association between liver fat and incident
AF. There are a number of possible explanations for why our
results differ from those observing an association between
liver fat and AF. First, given that 51% of the participants in the
Finnish study had hypertension, the results may not be
generalizable to community-based samples with lower rates of
Table 3. Logistic Regression Models for the Association Between Liver Fat (LPR) and Prevalent AF
Adjustment
Continuous Liver Fat (LPR) HS (LPR ≤0.33) HS (LPR ≤0.33) and Elevated ALT
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Age and sex 1.08 (0.84–1.38) 0.56 1.52 (0.85–2.73) 0.16 0.77 (0.30–1.96) 0.58
Multivariable* 1.01 (0.76–1.33) 0.94 1.29 (0.68–2.42) 0.43 0.83 (0.32–2.16) 0.70
Multivariable*+BMI 0.95 (0.71–1.27) 0.71 1.12 (0.58–2.18) 0.74 0.76 (0.29–1.99) 0.57
Data are shown as odds ratios (95% CIs) per SD decrease of the liver phantom ratio (increasing liver fat). AF indicates atrial ﬁbrillation; ALT, alanine aminotransferase; BMI, body mass
index; HS, hepatic steatosis; LPR, liver phantom ratio; MV, multivariable; OR, odds ratio.
*Multivariable adjustment included sex, age, systolic blood pressure, diastolic blood pressure, current smoking, use of antihypertensive medication, prevalent diabetes mellitus, history of
heart failure, and history of myocardial infarction.
Table 4. Cox Proportional-Hazards Models Relating Liver Fat (LPR) to Incidence of AF
Models
Continuous Liver Fat (LPR) HS (LPR ≤0.33) HS (LPR ≤0.33) and Elevated ALT
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Age- and sex-adjusted 1.08 (0.93–1.26) 0.31 1.10 (0.75–1.62) 0.62 1.16 (0.71–1.87) 0.56
MV* adjusted 1.05 (0.90–1.23) 0.54 1.04 (0.70–1.53) 0.86 1.10 (0.67–1.80) 0.70
MV*+BMI adjusted 1.02 (0.87–1.20) 0.78 0.96 (0.64–1.45) 0.86 1.06 (0.65–1.74) 0.81
Data are shown as hazard ratios (95% CIs) per SD decrease of the liver phantom ratio (increasing liver fat). AF indicates atrial ﬁbrillation; ALT, alanine aminotransferase; BMI, body mass
index; HR, hazard ratio; HS, hepatic steatosis; LPR, liver phantom ratio; MV, multivariable.
*Multivariable adjustment included sex, age, systolic blood pressure, diastolic blood pressure, current smoking, use of antihypertensive medication, prevalent diabetes mellitus, history of
heart failure, and history of myocardial infarction.
DOI: 10.1161/JAHA.116.005227 Journal of the American Heart Association 5
Liver Fat and Atrial Fibrillation Long et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on O
ctober 17, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
prevalent hypertension or other cardiovascular risk factors.
Second, in contrast to our method of deﬁning AF, in the
Finnish study, AF was deﬁned based on hospital discharge
diagnoses. As such, it is possible that individuals with HS
were more likely to be hospitalized for AF compared to those
without HS, which may have introduced a systematic bias.
Indeed, those with HS also tended to have a higher burden of
comorbid cardiovascular disease, which may complicate the
management of AF and require hospitalization instead of
outpatient management. Importantly, there were only 153
incident cases of AF noted over 12 years of follow-up in our
study. As such, we may not have had sufﬁcient power to
detect modest associations between liver fat and AF.
Strengths and Limitations
The major strengths of our investigation include the use of a
well-phenotyped, community-dwelling sample within the con-
text of a longitudinal cohort study with systematic follow-up
procedures and detailed outcome ascertainment. However, a
number of limitations are important to consider. First, MDCT
is most sensitive and speciﬁc for moderate-to-severe liver fat
and we cannot comment on the association between mild
liver fat or more-severe forms of NAFLD, including steato-
hepatitis or liver ﬁbrosis, and AF. Second, our sample was
constituted middle-aged to older adults, largely of European
descent. The generalizability of our ﬁndings to different races
or ethnicities or older or younger age individuals is not known.
Also, because the prevalence of AF is low, we had limited
power. Finally, because AF is often asymptomatic, it is
possible we missed AF during case ascertainment despite a
careful assessment for outcomes.
Conclusion
Our ﬁndings, if conﬁrmed, suggest that liver fat is not
associated with AF over and above traditional AF risk factors
in middle-aged to older, community-dwelling adults. Although
FHS participants with increased liver fat had a higher burden of
adverse cardiovascular traits, they did not have an increased
prevalence of AF and were not at substantively increased risk
for developing AF over a 12-year period. Additional prospective
studies are needed to validate our ﬁndings.
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